Observational study of clinical outcomes of eribulin mesylate in metastatic breast cancer after cyclin-dependent kinase 4/6 inhibitor therapy

• Published in: Future oncology (London, England) Vol. 15; no. 34; pp. 3935 - 3944
• Main Authors: Mougalian, Sarah S, Feinberg, Bruce A, Wang, Edward, Alexis, Karenza, Chatterjee, Debanjana, Knoth, Russell L, Nero, Damion, Miller, Talia, Liassou, Djibril, Kish, Jonathan K
• Format: Journal Article
• Language: English
• Published: England Future Medicine Ltd 01-12-2019
• Subjects: Adult; Aged; Aminopyridines - administration & dosage; Aminopyridines - adverse effects; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - adverse effects; Benzimidazoles - administration & dosage; Benzimidazoles - adverse effects; breast; Breast cancer; Breast Neoplasms - mortality; Breast Neoplasms - pathology; Breast Neoplasms - therapy; Chemotherapy; Chemotherapy, Adjuvant - methods; Chemotherapy-Induced Febrile Neutropenia - epidemiology; Chemotherapy-Induced Febrile Neutropenia - etiology; Clinical outcomes; Cyclin-Dependent Kinase 4 - antagonists & inhibitors; Cyclin-Dependent Kinase 6 - antagonists & inhibitors; Cyclin-dependent kinases; Data collection; Diarrhea - chemically induced; Diarrhea - epidemiology; Disease Progression; Female; Follow-Up Studies; Furans - administration & dosage; Furans - adverse effects; hormonal therapy; Humans; Ketones - administration & dosage; Ketones - adverse effects; Mastectomy; Metastasis; Middle Aged; Neoadjuvant Therapy - methods; Neutropenia; Observational studies; outcomes research; Palliative Care - methods; Palliative Care - trends; palliative/end-of-life care; Patients; Peripheral Nervous System Diseases - chemically induced; Peripheral Nervous System Diseases - epidemiology; Peripheral neuropathy; Piperazines - administration & dosage; Piperazines - adverse effects; Progression-Free Survival; Protein Kinase Inhibitors - administration & dosage; Protein Kinase Inhibitors - adverse effects; Purines - administration & dosage; Purines - adverse effects; Pyridines - administration & dosage; Pyridines - adverse effects; real-world evidence; Treatment Outcome; United States - epidemiology; Womens health; Young Adult; United States; United States > US; hormonal therapy; palliative/end-of-life care; real-world evidence; outcomes research; breast; chemotherapy
• ISSN: 1479-6694; 1744-8301
• DOI: 10.2217/fon-2019-0537

To examine the effectiveness of eribulin mesylate for metastatic breast cancer post cyclin-dependent kinase inhibitor (CDKi) 4/6 therapy.
US community oncologists reviewed charts of patients who had received eriublin from 3 February 2015 to 31 December 2017 after prior CDKi 4/6 therapy and detailed their clinical/treatment history, clinical outcomes (lesion measurements, progression, death) and toxicity.
Four patient cohorts were created according to eribulin line of therapy: second line, third line, per US label and fourth line with objective response rates/clinical benefit rates of 42.2%/58.7%, 26.1%/42.3%, 26.7%/54.1% and 17.9%/46.4%, respectively. Median progression-free survival/6-month progression-free survival (79.5% of all patients censored) by cohort was: 9.7 months/77.3%, 10.3 months/71.3%, not reached/70.4% and 4.0 months/0.0%, respectively. Overall occurrence of neutropenia = 23.5%, febrile neutropenia = 1.3%, peripheral neuropathy = 10.1% and diarrhea = 11.1%.
Clinical outcome and adverse event rates were similar to those in clinical trials and other observational studies. Longer follow-up is required to confirm these findings.